NEW YORK – After publishing positive results from a clinical validation study of its PrismRA assay, Scipher Medicine is gearing up to launch the test by the end of the summer for clinical use in guiding drug treatment decisions for patients with rheumatoid arthritis (RA).
Company researchers and academic collaborators reported the retrospective validation results last week in the journal Network and Systems Medicine.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
